Vascugen is pioneering advancements in regenerative medicine, specifically targeting vascular diseases that affect millions globally. The company focuses on developing cell therapies that aim to restore blood flow in tissues suffering from ischemia, a condition characterized by insufficient blood supply. Utilizing induced pluripotent stem cell (iPSC) technology, Vascugen has established a proprietary cell differentiation process that allows for the consistent and scalable production of their regenerative medicine products. Unlike traditional treatments that rely on stimulating existing blood vessels through indirect mechanisms, Vascugen's innovative approach directly promotes the formation of new blood vessels, a process known as vasculogenesis, thereby addressing the limitations of previous therapies.

The company’s research is particularly relevant for severe vascular conditions such as critical limb ischemia and diabetic retinopathy, which currently have limited treatment options. Vascugen's regenerative medicine strategies are designed to restore vascular function, potentially reducing the need for major amputations and improving patient outcomes. Additionally, Vascugen is exploring applications in tissue engineering, where their vasculogenic cells can be integrated into larger structures to ensure proper blood perfusion, thus enhancing the viability of engineered tissues and organs. This multifaceted approach positions Vascugen at the forefront of regenerative medicine, with the potential to significantly impact the treatment landscape for vascular degenerative diseases.

United States

Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death for whom few to no treatment options remain. The company’s lead product is an allogeneic vasculogenic cell – a cell with the potential to forge new blood vessels in oxygen-starved tissues. The vasculogenic cell product is manufactured from induced pluripotent stem cells (iPSCs), which provide a limitless source from which to produce off-the-shelf, cryopreserved doses at scale.

Vascugen

Company Details